simendan has been researched along with Abnormality, Heart in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 18 (81.82) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Akcan-Arikan, A; Alexander, PMA; Shekerdemian, LS | 1 |
| Cui, C; Fan, Y; Tan, Q; Wang, A; Wang, F; Wang, G; Wang, J; Zhang, J; Zi, J | 1 |
| Cześniewicz, P; Kusa, J; Mazurak, M | 1 |
| Hummel, J; Rücker, G; Stiller, B | 2 |
| Dempsey, E; Rabe, H | 1 |
| Castellheim, A; Keski-Nisula, J; Ricksten, SE; Romlin, BS; Suominen, PK; Synnergren, M; Thorlacius, EM; Vistnes, M; Wåhlander, H | 1 |
| Favia, I; Ricci, Z; Vitale, V | 1 |
| Burkhardt, BE; Rücker, G; Stiller, B | 1 |
| Freeman, LJ; Rafiq, I | 1 |
| Cantinotti, M; Giordano, R; Mannacio, VA; Palma, G | 1 |
| Boethig, D; Goerler, H; Huber, D; Osthaus, WA; Sasse, M; Sümpelmann, R; Winterhalter, M | 1 |
| Anslot, C; Clement de Clety, S; Detaille, T; Joomye, R; Matta, A; Momeni, M; Poncelet, AJ; Rennotte, MT; Rubay, J; Veyckemans, F | 1 |
| Bravo, MC; Bravo, Mdel C; Cabañas, F; López, P; Pellicer, A; Pérez-Fernández, E; Pérez-Rodríguez, J; Quero, J | 1 |
| Bautista-Hernandez, V; Fynn-Thompson, F; Portela, F; Sanchez-Andres, A | 1 |
| Kantor, PF; Timberlake, K | 1 |
| Cogo, PE; Di Chiara, L; Favia, I; Garisto, C; Ricci, Z; Vitale, V | 1 |
| Freynschlag, R; Gombotz, H; Hofer, A; Lechner, E; Leitner-Peneder, G; Mair, R; Rehak, P; Weinzettel, R | 1 |
| Arocas-Casañ, V; Blázquez-Álvarez, MJ; Cárceles-Barón, MD; de la Rubia-Nieto, A; Fernández de Palencia-Espinosa, MA | 1 |
| Bravo, MC; Buño, A; Cabañas, F; Castro, L; Labrandero, C; Lopez-Ortego, P; Lubomirov, R; Madero, R; Pellicer, A; Perez-Rodriguez, J; Quero, J; Riera, J | 1 |
| Braun, JP; Kastrup, M; Liu, J; Schneider, M | 1 |
| Antila, S; Boldt, T; Lehtonen, L; Palkama, T; Pesonen, E; Turanlahti, M | 1 |
5 review(s) available for simendan and Abnormality, Heart
| Article | Year |
|---|---|
Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
Topics: Assisted Circulation; Cardiac Output, Low; Cardiotonic Agents; Child, Preschool; Heart Defects, Congenital; Humans; Hydrazones; Infant; Intensive Care Units, Pediatric; Length of Stay; Postoperative Complications; Pyridazines; Randomized Controlled Trials as Topic; Respiration, Artificial; Simendan; Syndrome | 2017 |
The Use of Cardiotonic Drugs in Neonates.
Topics: Adrenal Cortex Hormones; Asphyxia Neonatorum; Cardiotonic Agents; Dobutamine; Dopamine; Heart Defects, Congenital; Humans; Hypotension; Infant, Newborn; Intensive Care Units, Neonatal; Milrinone; Neonatal Sepsis; Norepinephrine; Persistent Fetal Circulation Syndrome; Shock; Simendan; Vasoconstrictor Agents; Vasopressins | 2019 |
Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Heart Defects, Congenital; Humans; Hydrazones; Infant; Infant, Newborn; Milrinone; Postoperative Complications; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Syndrome; Time Factors | 2015 |
Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
Topics: Assisted Circulation; Cardiac Output, Low; Cardiotonic Agents; Coronary Care Units; Heart Defects, Congenital; Humans; Hydrazones; Length of Stay; Postoperative Complications; Pyridazines; Randomized Controlled Trials as Topic; Respiration, Artificial; Simendan | 2017 |
Current pharmacologic management of pediatric heart failure in congenital heart disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Child; Diuretics; Heart Defects, Congenital; Heart Failure; Hemodynamics; Humans; Hydrazones; Incidence; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
7 trial(s) available for simendan and Abnormality, Heart
| Article | Year |
|---|---|
Prophylactic use of levosimendan in pediatric patients undergoing cardiac surgery: a prospective randomized controlled trial.
Topics: Biomarkers; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Child, Preschool; Double-Blind Method; Female; Heart Defects, Congenital; Hemodynamics; Humans; Incidence; Infant; Kaplan-Meier Estimate; Length of Stay; Male; Postoperative Complications; Prospective Studies; Respiration, Artificial; Simendan; Treatment Outcome | 2019 |
The Effect of Levosimendan Versus Milrinone on the Occurrence Rate of Acute Kidney Injury Following Congenital Heart Surgery in Infants: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Creatinine; Double-Blind Method; Female; Finland; Heart Defects, Congenital; Heart Septal Defects; Heart Septal Defects, Ventricular; Humans; Infant; Male; Milrinone; Prospective Studies; Simendan; Sweden; Tetralogy of Fallot | 2019 |
Levosimendan in congenital cardiac surgery: a randomized, double-blind clinical trial.
Topics: Blood Pressure; Cardiac Surgical Procedures; Child, Preschool; Double-Blind Method; Heart Defects, Congenital; Heart Rate; Humans; Hydrazones; Infant; Infant, Newborn; Infusions, Intravenous; Milrinone; Prospective Studies; Pyridazines; Simendan | 2011 |
Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial.
Topics: Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Heart Defects, Congenital; Humans; Hydrazones; Infant, Newborn; Infusions, Intravenous; Italy; Outcome Assessment, Health Care; Postoperative Complications; Pyridazines; Simendan | 2012 |
Levosimendan versus milrinone in neonates and infants after corrective open-heart surgery: a pilot study.
Topics: Analysis of Variance; Body Surface Area; Cardiac Output; Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agents; Double-Blind Method; Female; Heart Defects, Congenital; Humans; Hydrazones; Infant; Infant, Newborn; Intention to Treat Analysis; Male; Milrinone; Pilot Projects; Premedication; Pyridazines; Simendan; Statistics, Nonparametric | 2012 |
Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery.
Topics: Blood Pressure; Cardiotonic Agents; Cardiovascular Surgical Procedures; Cerebrum; Heart Defects, Congenital; Heart Rate; Humans; Hydrazones; Infant, Newborn; Infusions, Intravenous; Oxygen; Pyridazines; Simendan; Spectroscopy, Near-Infrared; Time Factors; Vasodilator Agents | 2013 |
Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery.
Topics: Biological Availability; Cardiac Catheterization; Cardiotonic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography, Doppler; Electrocardiography; Female; Follow-Up Studies; Heart Defects, Congenital; Hemodynamics; Humans; Hydrazones; Infant; Infusions, Intravenous; Male; Preoperative Care; Pyridazines; Simendan; Single-Blind Method; Survival Rate; Treatment Outcome | 2004 |
10 other study(ies) available for simendan and Abnormality, Heart
| Article | Year |
|---|---|
Another Outcome Lost to the Benefits of Levosimendan?
Topics: Acute Kidney Injury; Cardiotonic Agents; Heart Defects, Congenital; Humans; Milrinone; Simendan | 2019 |
Levosimendan as a bridge to heart transplant in a 16-year-old patient with univentricular heart.
Topics: Adolescent; Heart Defects, Congenital; Heart Transplantation; Heart Ventricles; Humans; Simendan; Univentricular Heart | 2020 |
The vasoactive-inotropic score and levosimendan: time for LVIS?
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Child; Drug Therapy, Combination; Heart Defects, Congenital; Humans; Hydrazones; Myocardial Contraction; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents | 2013 |
Pulsed levosimendan therapy in the management of chronic end stage cardiac failure in 'adult congenital heart disease'.
Topics: Adult; Cardiac Surgical Procedures; Cardiotonic Agents; Disease Progression; Female; Heart Defects, Congenital; Heart Failure; Humans; Hydrazones; Life Expectancy; Male; Middle Aged; Postoperative Complications; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Treatment Outcome | 2015 |
First Experience With Levosimendan Therapy After Correction of Congenital Heart Disease.
Topics: Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Child; Child, Preschool; Female; Heart Defects, Congenital; Hemodynamics; Humans; Hydrazones; Infant; Infusions, Intravenous; Male; Postoperative Care; Pyridazines; Simendan | 2017 |
First experiences with intraoperative Levosimendan in pediatric cardiac surgery.
Topics: Cardiac Output; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Heart; Heart Defects, Congenital; Hemodynamics; Humans; Hydrazones; Infant; Infant, Newborn; Infusions, Intravenous; Intraoperative Period; Lactic Acid; Length of Stay; Oxygen; Postoperative Complications; Pyridazines; Respiration, Artificial; Retrospective Studies; Simendan; Transposition of Great Vessels | 2009 |
Acute effects of levosimendan on cerebral and systemic perfusion and oxygenation in newborns: an observational study.
Topics: Blood Pressure; Cardiac Output, Low; Cardiotonic Agents; Cerebrovascular Circulation; Heart Defects, Congenital; Heart Rate; Hemoglobins; Humans; Hydrazones; Infant, Newborn; Lactic Acid; Prospective Studies; Pyridazines; Respiration; Simendan; Statistics, Nonparametric | 2011 |
Pharmacologic therapy of heart failure in children: part of a special series on paediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Cardiotonic Agents; Child; Digoxin; Diuretics; Heart Defects, Congenital; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
[Retrospective descriptive study about the use of levosimendan in children undergoing surgical correction for congenital heart disease].
Topics: Cardiotonic Agents; Child, Preschool; Comorbidity; Compassionate Use Trials; Coronary Circulation; Down Syndrome; Drug Evaluation; Female; Heart Defects, Congenital; Hemodynamics; Humans; Hydrazones; Hypotension; Infant; Infant, Newborn; Kaplan-Meier Estimate; Male; Myocardial Ischemia; Postoperative Complications; Potassium Channels; Pyridazines; Retrospective Studies; Salvage Therapy; Simendan; Tachycardia | 2012 |
Treatment of acute heart failure in an infant after cardiac surgery using levosimendan.
Topics: Cardiotonic Agents; Female; Heart Arrest; Heart Defects, Congenital; Humans; Hydrazones; Infant; Postoperative Complications; Pyridazines; Simendan | 2004 |